分子標的薬アプデート 2018
|
|
|
- ことこ みつだ
- 5 years ago
- Views:
Transcription
1
2 Primary imatinib, (CML IV) 5-year survival 93% n = 2830 Survival probability IFN or SCT, (CML IIIA) 5-year survival 71% IFN or SCT, (CML III) 5-year survival 63% IFN, year survival 53% Hydroxyurea, Busulfan, year survival 38% Year after diagnosis German CML Study Group, 2008
3 Wikipedia,
4 Isotani M, JVIM, 2008 Druker BJ, J Clin Invest, 2000 Cohen MH, Clin Cancer Res, 2002
5 London CA, Clin Cancer Res, 2003 London CA, Vet Compar Oncol, 2011 McQuown B, VCS Proc, 2014 Berger EP, ACVIM Proc, 2017 London CA, Clin Cancer Res, 2003 London CA, Clin Cancer Res, 2009 London CA, Clin Cancer Res, 2003 Bernabe LF, BMC Vet Res, 2013
6 Bernabe LF, BMC Vet Res, 2013 London CA, Clin Cancer Res, 2003
7 London CA, Clin Cancer Res, 2009 ALT London CA, Clin Cancer Res, 2009 p=
8 GIST 34
9 p= Tjostheim SS, JVIM, 2016; Azizi M, N Engl J Med, 2008; Demetri GD, Lancet, 2006; Chu TF, KLancet, 2007; Maki RG, J Clin Oncol, 2005; Kane RC, Clin Cancer Res, 2006 Rassnick KM, JVIM, 1999 Rassnick KM, JVIM, 2008 Henry CJ, JAVMA, 2007 Rassnick KM, JVIM, 2008 Weishaar KM, JVIM, 2017 Rassnick KM, Vet Comp Oncol, 2010 McCaw DL, JVIM, 1997 Grant IA, JVIM, 2008 McCaw DL, JVIM, 1994 Stanclift RM, JAVMA, 2008,, 2009 * Rassnick Henary Rassnick ** SD 1
10 n Thamm DH, JVIM, 1999 Camps-Palau MA, Vet Comp Oncology, 2007 Taylor F, JSAP, 2009 Cooper M, Vet Comp Oncol, 2009 Rassnick KM, Vet Comp Oncol, Rassnick KM, JVIM, 1999, 2. Rassnick KM, JVIM, 2008, 3. Henry CJ, JAVMA, 2007, 4. Rassnick KM, JVIM, 2008, 5. Rassnick KM, Vet Comp Oncol, 2010, 6. Thamm DH, JVIM, 1999, 7. Camps-Palau MA, Vet Comp Oncol, 2007, 8. Taylor F, JSAP, 2009, 9. Cooper M, Vet Comp Oncol, 2009, 10. Rassnick KM, Vet Comp Oncol, 2010, 11. Weishaar KM, JVIM, 2017 VBL: CPM: PRD n Thamm DH, JVIM, 1999 Davies DR, JAAHA, 2004 Hayes A, Vet Comp Oncol, 2007 Camps-Palau MA, Vet Comp Oncol, 2007 Cooper M, Vet Comp Oncol, 2009 Rassnick KM, Vet Comp Oncol, 2010 * c-kit Downing S, Am J Vet Res, 2002 Zemke D, Vet Pathol, 2002
11 n KIT KIT Hahn KA, JVIM, 2008, 2. Smrkovski OA, Vet Comp Oncol, 2013, 3. London CA, Clin Cancer Res, Weishaar KM, JVIM, 2017 Hahn KA, JVIM, 2008 London CA, Clin Cancer Res, 2009 London CA, Clin Cancer Res, 2009
12 n KIT % KIT KIT 1. Isotani M, JVIM, 2008, 2:,, 2010, 3. Robat C, Vet Comp Oncol, 2012, 4. Burton JH, JVIM, Grant J, JSAM,
13 p=0.002 Burton JH, JVIM, 2015 p=0.07 Smrkovski OA, Vet Comp Oncol, 2013 c-kit p=0.009 p=0.008 p=0.274 p=0.411 Hahn, KA, JVIM, 2008 c-kit c-kit
14 PDGFR= VEGFR= London CA, Vet Compar Oncol, 2011 % n=32 n=23 n=15 n=8 n=7 London CA, Vet Compar Oncol, 2011
15 London CA, Vet Compar Oncol, 2011 London CA, Vet Compar Oncol, 2011 p= Kim C, Can Vet J, 2017 Laver T, Vet Compar Oncol, 2017
16
17 More? McQuown B, VCS Proc, 2014
18 21 21
19 2cm Berger EP, ACVIM Proc, MGIST c-kit MGIST c-kit
20 n= 126) Piro CPM: London C, PLos One, 2015 n= 81) p=0.274 p=0.08 Piro CPM: London C, PLos One, 2015 Gardner HL, BMC Vet Res, 2015
21 Robat C, Vet Comp Oncol, 2012 Rippy SB, BMC Vet Res, 2016 Pan X, Vet Comp Oncol, 2014 Burton JH, JVIM, 2015
22 Bavcar S, Vet J, 2017 Pellin MA, Vet Comp Oncol, 2016 Wounda RM, Vet Comp Oncol, 2017
23 Lachowicz JL, JVIM, 2005 c-kit Isotani M, Br J Haematol, 2010 Isotani M, Vet Immunol Immunopathol, 2006 p= Olmsted GA, J Feline Med Surg, 2016
24 Merrick CH, Vet Comp Oncol Harper A, J Feline Med Surg, 2016
25 Berger EP, J Feline Med Surg, 2017 p p Wiles V, J Feline Medicine and Surgery, 2016
26 OS PFS p= p= Wiles V, J Feline Medicine and Surgery, mg/kg EOD N. Holtermann, Vet Comp Oncol. 2017
27 c-kit
化学療法剤の適切な使い方について
1 2 3 4 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, 1988 8 Cancer: Principles & Practice of Oncology
橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
10K1A NASA () SPACE ATLAS Freedom H2A NASA 1
10O1A 10 10 1 10K1A NASA () SPACE ATLAS 40 1957 1969 10 1986 1990 Freedom 20 000 H2A NASA 1 10K1A 100 10 21 40 1996 ( 200 () 2 10S1A 10 8 57 250 1 10S1A 20 200mmm 2 10S1B 18 18 1 10S1B 40 10 20 2 10S1C
untitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
030801調査結果速報版.PDF
15 8 1 15 7 26 1. 2. 15 7 27 15 7 28 1 2 7:13 16:56 0:13 3km 45 346 108 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3. 3.1 26 7 10 1 20cm 2 1 2 45 1/15 3 4 5,6 3 4 3 5 6 ( ) 7,8 8 7 8 2 55 9 10 9 10
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
肺癌第50巻第4号
1 Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan; 2 Department of Thoracic Surgery, Aichi Cancer Center, Japan;
日本皮膚科学会雑誌第121巻第11号
β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis
Single slice helical CT CT 1 2005 1 4 1. CT Anti-Lung Cancer Association: ALCA 1-5) 1993 9 10 ALCA (Nawa 6) ) single slice helical CT 10mm CT 2. 1 (http://www.thoracic-ctscreening.org/jpn/index.html )
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
ito.dvi
1 2 1006 214 542 160 120 160 1 1916 49 1710 55 1716 1 2 1995 1 2 3 4 2 3 1950 1973 1969 1989 1 4 3 3.1 3.1.1 1989 2 3.1.2 214 542 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
日本皮膚科学会雑誌第120巻第5号
1 2 3 4 5 6 A B 1 2 α β 3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3
untitled
47 48 10 49 2005.6.1 17 500 50 1988 1994.1.1 16 22 51 18 1989 2005 17 2006 18 4 12 18 2007 19 1 12 2007 19 H18.8. J.H. 20 19 52 53 42.9 54 50 50 3080 55 30 100 56 57 22 96 6.8 9.4 31.44 58 10 780 250 59
日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
untitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
) km 200 m ) ) ) ) ) ) ) kg kg ) 017 x y x 2 y 5x 5 y )
001 ) g 20 g 5 300 g 7 002 720 g 2 ) g 003 0.8 m 2 ) cm 2 004 12 15 1 3 1 ) 005 5 0.8 0.4 ) 6 006 5 2 3 66 ) 007 1 700 12 ) 008 0.315 ) 009 500 g ) kg 0.2 t 189 kg 17.1 kg 010 5 1 2 cm 3 cm )km 2-1 - 011
取扱説明書 [d-01H]
![取扱説明書 [d-01H]](/thumbs/42/23082695.jpg "取扱説明書 [d-01H]")
d-01h 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1 2 19 3 1 2 4 3 20 4 21 1 2 3 4 22 1 2 1 2 1 23 1 1 2 24 25 26 1 1 1 2 27 1 2 3 28 29 1 2 1 2 3 30 1 2 3 4 5 1 2 3 31 1 2 3 4 32 33 34 1 35 1 36 37
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
Atlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
日本皮膚科学会雑誌第121巻第12号
Geriatrics Akt Dermato Eur J Vasc Endovasc Surg Ann R Coll Surg Engl Br J Surg Cochrane Database Syst Rev Cochrane Database Syst Rev Cochrane Database Syst Rev Cochrane Database Syst Rev Int wound J Eur
EP7000取扱説明書
EP7000 S0109-3012 3 47 811 1213 1419 2021 53 54 5560 61 6263 66 2223 2427 2830 3133 3436 3740 4142 4344 45 46 4750 5152 2 4 5 6 7 1 3 4 5 6 7 8 9 15 16 17 18 13 EP7000 2 10 11 12 13 14 19 20 21 22 23 24
VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
Microsoft Word - ゴールドコーストマラソン2014.docx
2014 2014 7 3 7 14:25 16:20 22:25 6:25 10:55 19:00 22:55 0:35 42.195Km 7,300km 537,844 2013 6 30 6 2 1 Dr. 1 20 10 Q1 Q1 8m 2 7 4 15 J B H..S 45 30 7 20 49 20 15 3 45 4 3 50 28 35 km 40km 4 4 6 15km 20km
- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...
取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
262014 3 1 1 6 3 2 198810 2/ 198810 2 1 3 4 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 2... 2... 4... 5... 9... 9... 10... 10... 10... 10... 13 2... 13 3... 15... 15... 15... 16 4...
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 () - 1 - - 2 - - 3 - - 4 - - 5 - 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
卵巣癌の治療
K-net:2008.7.17 85 90 8 10 20 (FIGO) a (FIGO) b (FIGO) c (FIGO) a (FIGO) b (FIGO) c (FIGO) (FIGO) (FIGO) Risk factors Preventive factors Risk factors 35 PCO, Preventive factors? Relative risk
/27 (13 8/24) (9/27) (9/27) / / / /16 12
79 7 79 6 14 7/8 710 10 () 9 13 9/17 610 13 9/27 49 7 14 7/8 810 1 15 8/16 11 811 1 13 9/27 (13 8/24) (9/27) (9/27) 49 15 7/12 78 15 7/27 57 1 13 8/24 15 8/16 12 810 10 40 1 Wikipedia 13 8/18, 8/28 79
8 8 0
,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7
レジャー産業と顧客満足の課題
1 1983 1983 2 3700 4800 5500 3300 15 3 100 1000 JR 4 14 2000 55% 72% 1878 2000 5 ( ) 22 1,040 5 946 42 15 25 30 30 4 14 39 1 24 8 6 390 33 800 34 34 3 35 () 37 40 1 50 40 46 47 2 55 4.43 4 16.98 40 55
ライフサイエンス関連 コラーゲン・ゼラチン製品案内 2015.12
3 mg/ml ph 3 4 8 1 Type I-A Type I-P Type I-A Type I-C Type III Type III Type IV Type IV TEL 072-820-3079 FAX 072-820-3095 4 8 4 Type I-A 20mL 1 F-12 MEM 5mL 1 4mL 5 10F-12MEM DFDME F-12 1 1199 5 DMERPMI-1640
1 1 1 11 25 2 28 2 2 6 10 8 30 4 26 1 38 5 1 2 25 57ha 25 3 24ha 3 4 83km2 15cm 5 8ha 30km2 8ha 30km2 4 14
3 9 11 25 1 2 2 3 3 6 7 1 2 4 2 1 1 1 11 25 2 28 2 2 6 10 8 30 4 26 1 38 5 1 2 25 57ha 25 3 24ha 3 4 83km2 15cm 5 8ha 30km2 8ha 30km2 4 14 60 m3 60 m3 4 1 11 26 30 2 3 15 50 2 1 4 7 110 2 4 21 180 1 38
![かんたん操作ガイド[arrows M02]](/thumbs/39/20071242.jpg "かんたん操作ガイド[arrows M02]")
![かんたん操作ガイド[arrows RM02]](/thumbs/39/20475147.jpg "かんたん操作ガイド[arrows RM02]")
![かんたん操作ガイド[arrows M03]](/thumbs/42/22941141.jpg "かんたん操作ガイド[arrows M03]")
234 50cm
234 50cm () 1 10 2 3 4 1 5 6 2 2 1 7 ( ー ) っ ー っ 8 1 2 10 10 2m 4m 6m 15m 457-2472 585-1154 9 10 2 60 2 100 RC SRC 30 80 500 1 500 500 ) 10 B b A 2 A B 2m 457-2473 585-1154 11 20m a 2m 3 3 1m 75cm 120cm
km2 km2 km2 km2 km2 22 4 H20 H20 H21 H20 (H22) (H22) (H22) L=600m L=430m 1 H14.04.12 () 1.6km 2 H.14.05.31 () 3km 3 4 5 H.15.03.18 () 3km H.15.06.20 () 1.1km H.15.06.30 () 800m 6 H.15.07.18
…h…L…–…†…fi…g1
RY RO RR RW LN LM LB LC MH MG MB RD RM RG LD CW SB VR BB EB PW PY PP PG PB 0 contents WR LR MR BR DR PM SM MC CB BO 0 P P7 P P5 P9 P 0 P4 P48 P54 P60 P66 P 04 RY RO RR RW RD RM RG LN LM LB LC LD MH MG
MH MH 9.50 8.50 9.40 8.40 9.30 9.20 8.30 9.10 9.00 8.20 8.90 8.80 8.10 8.70 8.60 8.00 8.50 7.90 8.40 8.30 7.80 8.20 8.10 7.70 8.00 7.60 7.90 7.80 7.50 7.70 7.60 7.40 1 7.50 7.40 7.30 2 7.30 7.20 7.20
がん学会教育講演 化学療法2016 ホームページ用.pptx
日本獣医がん学会教育講演化学療法 抗がん治療の治療効果の判定 埼玉動物医療センター腫瘍科林宝謙治 WHO と RECIST WHO RECIST 効果判定 2 方向で計測 最長径 CR 病変無し 病変無し PR 50% 縮小 30% 縮小 SD PR< 病変
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
1
1 5% 4% 11% 8% 13% 12% 10% 6% 17% 6% 8% 4% 6% 6% 2% 17% 17% 12% 14% 16% 6% 37% 11% 17% 35% 2 (N=6,239) 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 1,585 1,126 950 494 345 296 242 263 191 150 131 116
iii iv v vi 21 A B A B C C 1 1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 19 22 30 39 43 48 54 60 65 74 77 84 87 89 95 101 12 20 23 31 40 44 49 55 61 66 75 78 85 88 90 96 102 13 21 24 32 41 45 50 56 62 67 76 79
PowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
参考資料509
参考資料509 参考資料 510 参考資料 511 参考資料 512 参考資料 513 参考資料 F( day W pdg/cm Z ( 514 参考資料 515 参考資料 516 参考資料 517 参考資料 518 参考資料 519 参考資料 520 参考資料 521 参考資料 522 参考資料 523 参考資料 524 参考資料 525 参考資料 526 参考資料 527 参考資料 528 参考資料
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
阪神５年PDF.PDF
1995.1.17 N 0km 10 20 31 4,569 14,679 67,421 55,145 6,965 80 1,471 3,383 13,687 5,538 327 22 933 1,112 12,757 5,675 465 2 243 3,782 6,344 6,641 65 17 555 1,755 9,533 8,109 940 15 12 817 271 3,140 1 918
1,000m 875m1 6km
1,000m 875m1 6km 1,000m 875m 30 13 14 11 2 14 23 27 50 30 3 () 23 24 25 16,534 16,792 18,017 13,946 17,884 18,712 30,480 34,676 36,729 1 (25 ) () 395 1,420 1,343 1,756 1,364 1,599 1,184 1,278 1,619 1,324
私にとっての沖縄と独自性.PDF
6902117 2 1200km 48 11 46 36 40 (1) ( ) 3 1 1-1 1-2 2 (= ) 3 1. 14 14 ( ) ( 2001) ( ) ( ) 1390 1474 ( 2001) ( 4 ) ( ) 46 3000 ( ) = 5 1609 1602 ( 2001) 1-1 1-2 1-1 1-2 15 (2) 6 1314 ( ) (3) ( ) 1 ( 1993:48)
-1 - -2 - -3 - -4 - -5 - -6- -7 - 260-8 - -9 - - 10-104km2 194km 340 104km2 194km 340 -11 - - 12-10km 20km 30km 260 260 1km 2km 2000 10km 20km 30km 260 260 1km 2km 2000 260 260 1km 2km 2000 - 13 - ( 3
, , km 9.8km 10.5km 11.9km 14.4km 14.4km 34.1km 3.4km 31.7km 6.2km 7.3k
410 470 500 540 620 620 620 1,250 300 1,170 360 390 450 490 570 670 770 850 880 7.7km 9.8km 10.5km 11.9km 14.4km 14.4km 34.1km 3.4km 31.7km 6.2km 7.3km 8.9km 10.4km 12.9km 15.8km 19.0km 21.7km 22.4km 530
! 1 m 43 7 1 150 ( ) 100 ( ) 11.3m 30 800 ( ) 1680 20 15 1,253 ( ) 1,500 51 52 300 1 4 134 1000 3 600 ( ) 30 , 402 km (1702) ( 1 402 67 12 23 10 ( ) ( 25,000 ) (1701 ) 485 ( 20 ) 400 (1860 ) (1) (2)
untitled
60 547 547 4km [ ] 14 20 18 2,400 5,500 24 15 10,000 [ ] [ ] 1779 1779 1471-76 1914 1471-76 1779 1914 1779 1779 1914 1471-7676 1779 1471-76 1946 1914 59 8 25 30 1986 3km 2m 5 2km 18 6 [ ]
Microsoft Word - 01_表紙
1 2 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 7.0 190 km 30 62 63 64
渋谷区耐震改修促進計画
1 2 3 2 1,000 ( ) 1,500 ( ) 3 1,000 1 1,000 2,000 3 1,000 2,000 3 1,000 2,000 3 1,000 2,000 3 1,000 2,000 3 1,000 2,000 3 1,000 3 1,000 2,000 3 1,000 2,000 3 1,000 3 1,000 2 1,000 2,000 2 1,000 2,000 2
一太郎 13/12/11/10/9/8 文書
(1) 17 3 (2) (3) (1) 1 (2) 2 (1) (2) (3) (4) (5) (6) (7) (8) 3 (1) 50 12.5km 1km (2) 16 1900 (3) 65 65 19 14 17.5 (4) 34 31 22 335 133 (5) 104 321 3 4 4 43 4 4 4 () 5 6 (1) (2) 7 8 (1) (2)24 24 (3) 9 (4)
() () () 200,000 160,000 120,000 80,000 40,000 3.3 144,688 43,867 3.1 162,624 52,254 170,934 171,246 172,183 3 2.8 2.6 57,805 61,108 65,035 3.5 3 2.5 2 1.5 1 0.5 0 0 2 7 12 17 22 10.1 12.7 17 22.3 73.4
CISPR11 AM J55001(H22)
J55011H27 CISPR 11 5 (2009), Amd.1(2010) J55001(H22) 3 a) CISPR11 26 3 CISPR11 J55011 b) CISPR11 CISPR11 2 CISPR11 CISPR11 CISPR11 CISPR11 CISPR11 c) CISPR11 CISPR11 CISPR11 CISPR11 AM J55001(H22) 1 2
1) Delbet P: Retrocissement du choledoque. Cholecysto-duodenostomie. Bull Mem Soc Nat Chir 50: 1144-1146, 1924 2) Wiesner RH, LaRusso NF: Clinicopathologic Features of the Syndrome of Primary Sclerosing